Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik; Sifat Sharmin; Izanne Roos; Mark S Freedman; Harold Atkins; Joachim Burman; Jennifer Massey; Ian Sutton; Barbara Withers; Richard Macdonell; Andrew Grigg; Oivind Torkildsen; Lars Bo; Anne Kristine Lehmann; Eva Kubala Havrdova; Eva Krasulova; Marek Trneny; Tomas Kozak; Anneke van der Walt; Helmut Butzkueven; Pamela McCombe; Olga Skibina; Jeannette Lechner-Scott; Barbara Willekens; Elisabetta Cartechini; Serkan Ozakbas; Raed Alroughani; Jens Kuhle; Francesco Patti; Pierre Duquette; Alessandra Lugaresi; Samia J Khoury; Mark Slee; Recai Turkoglu; Suzanne Hodgkinson; Nevin John; Davide Maimone; Maria Jose Sa; Vincent van Pesch; Oliver Gerlach; Guy Laureys; Liesbeth Van Hijfte; Rana Karabudak; Daniele Spitaleri; Tunde Csepany; Riadh Gouider; Tamara Castillo-Trivino; Bruce Taylor; Basil Sharrack; John A Snowden

Journal article

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, Andrew Grigg, Oivind Torkildsen, Lars Bo, Anne Kristine Lehmann, Eva Kubala Havrdova, Eva Krasulova, Marek Trneny, Tomas Kozak, Anneke van der Walt, Helmut Butzkueven Show all

JAMA Neurology | American Medical Association | Published : 2023

DOI: 10.1001/jamaneurol.2023.1184

Download PDF

Abstract

IMPORTANCE: Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). OBJECTIVE: To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials. DESIGN, SETTING, AND PARTICIPANTS: This comparative treatment effectiveness study included 6 specialist MS centers with AHSCT programs and international MSBase registry between 2006 and 2021. The study included patients with relapsing-remitting MS treated with AHSCT, fingolimod, natalizumab, or ocrelizumab with 2 or more years study follow-up including 2 or more disability assessments. Patients were matched..

View full abstract

University of Melbourne Researchers

Tomas Kalincik Author

Sifat Sharmin Author

Izanne Roos Author

Richard MacDonell Author

Related Projects (3)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Personalised therapy to prevent disability in aggressive multiple sclerosis

Grants

Awarded by National Health and Medical Research Council of Australia

Awarded by Multiple Sclerosis Australia

Funding Acknowledgements

This study was financially supported by National Health and Medical Research Council of Australia (fellowship 1140766, project grant 1129189) and Multiple Sclerosis Australia (projects 19-800 and 22-2-103). Part of the data acquisition was funded by the MS Foundation of Canada.